CTSF Antibody

What is CTSF and why is it important in research?

CTSF (Cathepsin F) is a unique member of the Peptidase C1 protein family functioning as a thiol protease involved in intracellular degradation and protein turnover. In humans, the canonical protein has 484 amino acids with a molecular mass of 53.4 kDa and is primarily localized in lysosomes . Its uniqueness stems from having an extended N-terminal anterior region containing a cystatin domain, which distinguishes it from other cathepsins .

CTSF is important in research because:

• It may play regulatory roles in processing invariant chain associated with MHC class II, suggesting immune system involvement

• Mutations in the CTSF gene have been linked to adult-onset neuronal ceroid lipofuscinosis (ANCL) and frontotemporal dementia (FTD)

• It shows differential expression in various cancers with potential prognostic significance

• Its wide expression profile suggests broad physiological functions worth investigating

What tissues and cell types express CTSF?

CTSF shows a differential expression pattern across tissues:

• High expression tissues: Artery-Aorta, Brain (cerebellar hemisphere and cerebellum), Cervix (ectocervix and endocervix), Fallopian tube, Nerve (tibial), Ovary, Testis, and Uterus (TPM > 200)

• Cell types in lung tissue: Significantly higher expression in infiltrating immune cells (particularly macrophages) compared to alveolar or cancerous cells

• Cancer cell lines: Detected in HL-60, HeLa, K-562, MOLT-4, Raji, SW480, A549, and G361 cell lines

Interestingly, immunohistochemistry (IHC) analysis shows that CTSF is not detected in normal alveolar cells while medium staining is observed in macrophage cells in normal lung tissues .

What applications are CTSF antibodies validated for?

Based on commercial antibody validation data and research applications, CTSF antibodies are validated for multiple experimental techniques:

• Western Blot (WB): Most commonly validated application with typical dilutions of 1:500-1:1000

• Immunohistochemistry (IHC): Used to detect tissue expression patterns

• ELISA: Validated for quantitative detection

• Immunofluorescence (IF): For cellular localization studies

The optimal application varies by antibody source and specific clone, with Western Blot being the most widely validated technique across multiple suppliers .

How should researchers validate CTSF antibodies before experimental use?

Antibody validation is critical for experimental reliability. For CTSF antibodies, validation should include:

• Specificity validation:

  • Comparison between wildtype and knockdown/knockout tissue samples

  • Use of a second antibody targeting a different epitope of CTSF

  • Verification of single band at expected molecular weight (53.4 kDa) on Western blots

• Application-specific validation:

  • Validate for each experimental setup separately as specificity in one application does not guarantee specificity in another

  • Test fixation conditions for IHC/IF applications as they can affect epitope accessibility

  • Verify appropriate controls (positive/negative tissue controls known to express/not express CTSF)

• Documentation requirements:

  • Record batch information as batch-to-batch variability can significantly impact results

  • Document exact experimental conditions that work for your specific application

  • Validate across species if working with non-human samples

How does CTSF expression correlate with cancer prognosis, particularly in lung cancer?

CTSF demonstrates significant correlations with cancer prognosis, particularly in non-small cell lung cancer (NSCLC):

These findings suggest CTSF may function as a tumor suppressor in NSCLC, making it a potential prognostic biomarker warranting validation in larger cohorts.

What is the relationship between CTSF and immune response in cancer research?

CTSF demonstrates significant immunological functions that may explain its role in cancer:

This immunological dimension makes CTSF antibodies valuable tools for investigating tumor immunology and potential immunotherapy targets.

What approaches can be used to design antibodies with customized specificity profiles for CTSF?

Recent advances in antibody engineering allow for designing antibodies with customized specificity profiles:

• Biophysics-informed modeling approach:

  • Using high-throughput sequencing and machine learning techniques to identify different binding modes associated with specific ligands

  • Creating computational models that can disentangle multiple binding modes from selection experiments

  • Optimizing energy functions associated with each binding mode to design sequences with desired specificity profiles

• Implementation methodology:

  • Generate training data through phage display experiments with antibody selection against various ligand combinations

  • Build a computational model using shallow dense neural networks to capture binding mode energetics

  • Optimize sequence parameters to either minimize energy functions (for cross-specificity) or minimize energy for desired targets while maximizing for undesired targets (for high specificity)

This approach has been experimentally validated for creating antibodies with both specific and cross-specific binding properties, offering potential for generating highly specific CTSF antibodies .

How can researchers optimize CTSF antibody dilutions for specific applications?

Optimization of CTSF antibody dilutions is critical for experimental success and reproducibility:

• Western Blot optimization:

  • Start with manufacturer's recommended dilution range (typically 1:500-1:1000 for CTSF antibodies)

  • Perform titration experiments with at least three dilutions (e.g., 1:250, 1:500, 1:1000)

  • Evaluate signal-to-noise ratio at each dilution

  • Select dilution that provides optimal specific signal with minimal background

  • Validate across multiple sample types that express CTSF at different levels

• IHC/IF optimization:

  • Begin with positive control tissues known to express CTSF (cerebellum, macrophages)

  • Test multiple antigen retrieval methods to maximize epitope accessibility

  • Evaluate both the intensity of specific staining and background levels

  • Consider cell-type specific expression pattern differences when evaluating staining quality

• Optimization documentation:

  • Record exact antibody lot number, dilution, incubation time/temperature

  • Document buffer compositions and blockers used

  • Maintain detailed protocols for each successfully optimized application to ensure reproducibility

What are the challenges in using CTSF antibodies for investigating neurological disorders?

CTSF mutations have been linked to adult-onset neuronal ceroid lipofuscinosis (ANCL) and frontotemporal dementia (FTD), creating specific challenges when using CTSF antibodies in neurological research:

• Mutation-specific detection:

  • Some CTSF mutations may alter epitope structure, requiring validation that the antibody can detect mutant forms

  • Researchers should verify antibody recognition of specific CTSF mutants relevant to their study

• Tissue-specific considerations:

  • Brain tissue fixation can affect epitope accessibility

  • Autofluorescence in neuronal tissues may interfere with IF applications

  • Lipofuscin accumulation (characteristic of CTSF-related disorders) can create background staining issues

• Pathological sample handling:

  • Electron microscopy may be required alongside immunostaining to detect ultrastructural features of CTSF-related pathology

  • Combined approaches using skin biopsies and brain tissue may be necessary for comprehensive analysis

• Diagnostic applications:

  • When using CTSF antibodies for potential diagnostic applications in neurological diseases, extensive validation across multiple patient samples is required

  • Consider that CTSF mutations previously associated only with Kufs disease type B should now also be considered in patients with type A and early-onset dementia with frontal lobe symptoms

How can active learning strategies improve antibody-antigen binding prediction for CTSF research?

Recent advances in computational approaches can enhance CTSF antibody research efficiency:

• Active learning framework benefits:

  • Reduces the number of required experimental samples by up to 35%

  • Accelerates the learning process compared to random sampling approaches

  • Improves out-of-distribution prediction performance for antibody-antigen binding

• Implementation methodology:

  • Start with a small labeled subset of antibody-antigen binding data

  • Apply active learning algorithms to iteratively select the most informative samples for experimental validation

  • Retrain predictive models with newly labeled data

  • Continue cycle until desired prediction performance is achieved

• Applications for CTSF research:

  • Design CTSF-specific antibodies with improved binding characteristics

  • Predict cross-reactivity with other cathepsin family members

  • Optimize antibody sequences for specific applications (WB, IHC, etc.)

  • Reduce experimental costs by prioritizing the most informative experiments

This computational approach is particularly valuable for designing novel CTSF antibodies with customized specificity profiles.

What are the essential reporting standards when publishing research using CTSF antibodies?

To ensure reproducibility and experimental transparency when using CTSF antibodies, researchers should report:

• Antibody identification information:

  • Supplier name and catalog number (e.g., Boster Bio #A06600)

  • Clone number (for monoclonals) or host species (for polyclonals)

  • Lot number to account for batch-to-batch variability

  • RRID (Research Resource Identifier) if available

• Target antigen details:

  • Specific immunogen sequence used (e.g., "amino acids 270-484 of human CTSF (NP_003784.2)")

  • Whether a synthetic peptide or recombinant protein was used

  • The species of origin for the target sequence

• Validation evidence:

  • How specificity was confirmed (e.g., knockdown controls, blots showing expected MW)

  • Previous validation for the specific application and species used

  • References to published work using the same antibody

• Experimental conditions:

  • Exact dilution used (not just manufacturer's recommended range)

  • Incubation time and temperature

  • Detection method details

  • Complete buffer compositions

Adhering to these reporting standards is essential for experimental reproducibility and is increasingly required by journals.

How can researchers troubleshoot common issues with CTSF antibody experiments?

When troubleshooting CTSF antibody experiments, consider these methodological approaches:

• No signal or weak signal:

  • Verify CTSF expression in your sample type using reference databases (GTEx, TIMER)

  • Consider that CTSF is downregulated in some cancer tissues compared to normal tissues

  • Increase antibody concentration incrementally

  • Optimize antigen retrieval methods for IHC/IF

  • Extend primary antibody incubation time or temperature

• Multiple bands in Western Blot:

  • Consider post-translational modifications like glycosylation which are known to occur in CTSF

  • Test reducing vs. non-reducing conditions

  • Verify sample preparation protocols to prevent protein degradation

  • Check for cross-reactivity with other cathepsin family members

• High background:

  • Implement more stringent blocking procedures

  • Increase washing steps duration and number

  • Reduce secondary antibody concentration

  • Use appropriate negative controls (tissue/cells known not to express CTSF)

  • Consider that macrophages normally express CTSF and may contribute to background in mixed cell populations

• Inconsistent results between experiments:

  • Document exact antibody lot used as batch-to-batch variability is common

  • Standardize all aspects of protocols including fixation time for IHC/IF

  • Include positive control samples in every experiment

  • Consider using antibodies targeting different CTSF epitopes to confirm findings

What experimental controls are essential when using CTSF antibodies?

Rigorous experimental design for CTSF antibody research requires appropriate controls:

• Positive controls:

  • Tissues with known high CTSF expression (cerebellum, macrophages)

  • Cell lines with confirmed CTSF expression (HL-60, HeLa, K-562, A549)

  • Recombinant CTSF protein (particularly useful for Western Blot)

• Negative controls:

  • Primary antibody omission control

  • Isotype control (same species and isotype as primary antibody)

  • Tissues/cells with minimal CTSF expression (consider alveolar cells)

  • Pre-absorption control using the immunizing peptide when available

• Specificity controls:

  • CTSF knockdown or knockout samples when possible

  • Comparison with a second antibody targeting a different CTSF epitope

  • Parallel analysis with mRNA expression data when possible

• Downstream application controls:

  • For co-localization studies: markers for lysosomes (CTSF's primary location)

  • For functional assays: appropriate enzyme activity controls

  • For cancer studies: comparison of tumor vs. adjacent normal tissue

How can CTSF antibodies be utilized in cancer immunotherapy research?

CTSF antibodies offer valuable tools for cancer immunotherapy research based on its demonstrated immunological roles:

• Biomarker development:

  • Assess CTSF expression as a prognostic indicator in various cancer types

  • Correlate CTSF levels with response to existing immunotherapies

  • Develop IHC protocols for potential clinical applications

• Immune checkpoint interactions:

  • Investigate CTSF's relationship with immune checkpoint molecules (CTLA-4, LAG-3)

  • Use multiplex IHC with CTSF and checkpoint molecule antibodies to analyze co-expression patterns

  • Correlate expression patterns with clinical outcomes

• Tumor microenvironment characterization:

  • Study CTSF expression in tumor-associated macrophages versus cancer cells

  • Analyze relationships between CTSF-expressing cells and T-cell infiltration

  • Investigate the role of CTSF in antigen presentation within the tumor microenvironment

• Therapeutic target assessment:

  • Evaluate whether CTSF modulation could enhance response to existing immunotherapies

  • Develop in vitro assays to measure functional impacts of CTSF on immune cell activation

  • Study effects of CTSF inhibition or enhancement on tumor growth in preclinical models

These approaches leverage the observed correlations between CTSF expression, immune cell infiltration, and cancer prognosis to advance immunotherapy research.

What methodological approaches should be used when studying CTSF in neurodegenerative disorders?

When investigating CTSF in neurodegenerative disorders, researchers should employ these methodological approaches:

• Genetic analysis integration:

  • Screen for CTSF mutations in patients with adult-onset neuronal ceroid lipofuscinosis (ANCL) and frontotemporal dementia (FTD)

  • Consider CTSF genetic testing in both Kufs disease type A and B patients

  • Correlate genetic findings with antibody-based protein detection results

• Multi-modal tissue analysis:

  • Combine light microscopy, immunohistochemistry, and electron microscopy approaches

  • Analyze both brain tissue and peripheral samples (skin biopsies) when possible

  • Look specifically for lipofuscin accumulation and ultrastructural changes

• Disease-specific protocols:

  • For ANCL studies: focus on lysosomal pathology and storage material characteristics

  • For FTD investigations: examine frontal and temporal lobe pathology alongside motor system changes

  • Consider co-staining for other disease-associated proteins based on clinical presentation

• Functional assessments:

  • Measure CTSF enzymatic activity in addition to protein levels

  • Investigate effects of disease-associated mutations on protein localization and function

  • Develop cellular models expressing mutant CTSF to study pathogenic mechanisms

This integrated approach combines genetic, biochemical, and morphological analyses to comprehensively investigate CTSF's role in neurodegeneration.